Difficulty: Medium
Average Score: 87%
Practice
The following drugs are used as 'standard of care' when treating a patient with type II (hypoxic-hypercapnic) respiratory failure:
Correct answer
A
Rationale
In the treatment of type II (hypoxic-hypercapnic) respiratory failure, the standard of care is to administer supplemental oxygen, which is represented by option A - 35% oxygen. This is because patients with type II respiratory failure have a decreased ability to exchange oxygen and carbon dioxide efficiently, leading to hypoxemia and hypercapnia. Supplemental oxygen helps to improve oxygenation and reduce the workload on the respiratory system, thereby correcting the hypoxemia component of the condition.
Option B, Doxapram, is a respiratory stimulant that is primarily used to stimulate respiratory drive in certain situations such as drug-induced respiratory depression. It is not considered a standard treatment for type II respiratory failure.
Option C, Salbutamol, is a bronchodilator commonly used in conditions like asthma and COPD to relieve bronchoconstriction. While it can improve airflow in obstructive lung diseases, it does not address the underlying issue of impaired gas exchange seen in type II respiratory failure.
Option D, Methylprednisolone, is a corticosteroid that has anti-inflammatory properties and is often used in conditions like asthma exacerbations or allergic reactions. However, it is not a first-line treatment for type II respiratory failure, which is primarily a problem of gas exchange rather than inflammation.
Educationally, understanding the appropriate pharmacological interventions for different types of respiratory failure is crucial for healthcare professionals, especially those working in critical care settings. Knowing the rationale behind each treatment option helps in providing optimal care to patients and in making informed clinical decisions. It is important to differentiate between drugs used for symptomatic relief versus those targeting the underlying pathophysiology of a condition to ensure effective management.
Option B, Doxapram, is a respiratory stimulant that is primarily used to stimulate respiratory drive in certain situations such as drug-induced respiratory depression. It is not considered a standard treatment for type II respiratory failure.
Option C, Salbutamol, is a bronchodilator commonly used in conditions like asthma and COPD to relieve bronchoconstriction. While it can improve airflow in obstructive lung diseases, it does not address the underlying issue of impaired gas exchange seen in type II respiratory failure.
Option D, Methylprednisolone, is a corticosteroid that has anti-inflammatory properties and is often used in conditions like asthma exacerbations or allergic reactions. However, it is not a first-line treatment for type II respiratory failure, which is primarily a problem of gas exchange rather than inflammation.
Educationally, understanding the appropriate pharmacological interventions for different types of respiratory failure is crucial for healthcare professionals, especially those working in critical care settings. Knowing the rationale behind each treatment option helps in providing optimal care to patients and in making informed clinical decisions. It is important to differentiate between drugs used for symptomatic relief versus those targeting the underlying pathophysiology of a condition to ensure effective management.